Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
Identifieur interne : 000E66 ( Istex/Corpus ); précédent : 000E65; suivant : 000E67Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
Auteurs : B. Escudier ; S. Antoun ; B. Leclercq ; G. Nitenberg ; F. Farace ; E. Angevin ; F. Triebel ; T. Hercend ; A. Aboudaram ; M. BrandelySource :
- European Journal of Cancer [ 0959-8049 ] ; 1993.
Abstract
The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 106 U/m2 for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 106 U/m2 on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.
Url:
DOI: 10.1016/S0959-8049(05)80354-5
Links to Exploration step
ISTEX:4202F1CA50D86135E197329521FF9741A217E049Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to B. Escudier.</mods:affiliation></affiliation></author><author><name sortKey="Antoun, S" sort="Antoun, S" uniqKey="Antoun S" first="S." last="Antoun">S. Antoun</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Leclercq, B" sort="Leclercq, B" uniqKey="Leclercq B" first="B." last="Leclercq">B. Leclercq</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Nitenberg, G" sort="Nitenberg, G" uniqKey="Nitenberg G" first="G." last="Nitenberg">G. Nitenberg</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Farace, F" sort="Farace, F" uniqKey="Farace F" first="F." last="Farace">F. Farace</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Angevin, E" sort="Angevin, E" uniqKey="Angevin E" first="E." last="Angevin">E. Angevin</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Triebel, F" sort="Triebel, F" uniqKey="Triebel F" first="F." last="Triebel">F. Triebel</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Hercend, T" sort="Hercend, T" uniqKey="Hercend T" first="T." last="Hercend">T. Hercend</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Aboudaram, A" sort="Aboudaram, A" uniqKey="Aboudaram A" first="A." last="Aboudaram">A. Aboudaram</name><affiliation><mods:affiliation>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Brandely, M" sort="Brandely, M" uniqKey="Brandely M" first="M." last="Brandely">M. Brandely</name><affiliation><mods:affiliation>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4202F1CA50D86135E197329521FF9741A217E049</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/S0959-8049(05)80354-5</idno><idno type="url">https://api.istex.fr/document/4202F1CA50D86135E197329521FF9741A217E049/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E66</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title><author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to B. Escudier.</mods:affiliation></affiliation></author><author><name sortKey="Antoun, S" sort="Antoun, S" uniqKey="Antoun S" first="S." last="Antoun">S. Antoun</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Leclercq, B" sort="Leclercq, B" uniqKey="Leclercq B" first="B." last="Leclercq">B. Leclercq</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Nitenberg, G" sort="Nitenberg, G" uniqKey="Nitenberg G" first="G." last="Nitenberg">G. Nitenberg</name><affiliation><mods:affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Farace, F" sort="Farace, F" uniqKey="Farace F" first="F." last="Farace">F. Farace</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Angevin, E" sort="Angevin, E" uniqKey="Angevin E" first="E." last="Angevin">E. Angevin</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Triebel, F" sort="Triebel, F" uniqKey="Triebel F" first="F." last="Triebel">F. Triebel</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Hercend, T" sort="Hercend, T" uniqKey="Hercend T" first="T." last="Hercend">T. Hercend</name><affiliation><mods:affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Aboudaram, A" sort="Aboudaram, A" uniqKey="Aboudaram A" first="A." last="Aboudaram">A. Aboudaram</name><affiliation><mods:affiliation>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</mods:affiliation></affiliation></author><author><name sortKey="Brandely, M" sort="Brandely, M" uniqKey="Brandely M" first="M." last="Brandely">M. Brandely</name><affiliation><mods:affiliation>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="ISSN">0959-8049</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993">1993</date><biblScope unit="volume">29</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="724">724</biblScope><biblScope unit="page" to="728">728</biblScope></imprint><idno type="ISSN">0959-8049</idno></series><idno type="istex">4202F1CA50D86135E197329521FF9741A217E049</idno><idno type="DOI">10.1016/S0959-8049(05)80354-5</idno><idno type="PII">S0959-8049(05)80354-5</idno><idno type="ArticleID">05803545</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 106 U/m2 for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 106 U/m2 on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>B. Escudier</name><affiliations><json:string>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string><json:string>Correspondence to B. Escudier.</json:string></affiliations></json:item><json:item><name>S. Antoun</name><affiliations><json:string>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>B. Leclercq</name><affiliations><json:string>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>G. Nitenberg</name><affiliations><json:string>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>F. Farace</name><affiliations><json:string>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>E. Angevin</name><affiliations><json:string>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>F. Triebel</name><affiliations><json:string>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>T. Hercend</name><affiliations><json:string>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>A. Aboudaram</name><affiliations><json:string>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</json:string></affiliations></json:item><json:item><name>M. Brandely</name><affiliations><json:string>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</json:string></affiliations></json:item></author><articleId><json:string>05803545</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 106 U/m2 for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 106 U/m2 on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.</abstract><qualityIndicators><score>5.984</score><pdfVersion>1.3</pdfVersion><pdfPageSize>591 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1305</abstractCharCount><pdfWordCount>3440</pdfWordCount><pdfCharCount>21658</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>212</abstractWordCount></qualityIndicators><title>Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title><pii><json:string>S0959-8049(05)80354-5</json:string></pii><refBibs><json:item><author><json:item><name>SA Rosenberg</name></json:item><json:item><name>MT Lotze</name></json:item><json:item><name>LM Muul</name></json:item></author><host><volume>316</volume><pages><last>897</last><first>889</first></pages><author></author><title>N Engl J Med</title></host><title>A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone</title></json:item><json:item><author><json:item><name>RI Fisher</name></json:item><json:item><name>CA Coltman</name></json:item><json:item><name>JH Doroshow</name></json:item></author><host><volume>108</volume><pages><last>523</last><first>518</first></pages><author></author><title>Ann Intern Med</title></host><title>Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. A phase II clinical trial</title></json:item><json:item><author><json:item><name>S Negrier</name></json:item><json:item><name>T Philip</name></json:item><json:item><name>G Stoter</name></json:item></author><host><volume>25</volume><pages><last>28</last><first>21</first></pages><author></author><title>Eur J Cancer Clin Oncol</title></host><title>Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicenter study</title></json:item><json:item><author><json:item><name>SA Rosenberg</name></json:item><json:item><name>MT Lotze</name></json:item><json:item><name>LM Muul</name></json:item></author><host><volume>313</volume><pages><last>1492</last><first>1485</first></pages><author></author><title>N Engl J Med</title></host><title>Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</title></json:item><json:item><author><json:item><name>WH West</name></json:item><json:item><name>KW Tauer</name></json:item><json:item><name>JR Yanelli</name></json:item></author><host><volume>316</volume><pages><last>905</last><first>898</first></pages><author></author><title>N Engl J Med</title></host><title>Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer</title></json:item><json:item><author><json:item><name>DR Parkinson</name></json:item><json:item><name>RI Fisher</name></json:item><json:item><name>AA Rayner</name></json:item></author><host><volume>8</volume><pages><last>1636</last><first>1630</first></pages><author></author><title>J Clin Oncol</title></host><title>Therapy of renal cell cancer carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hydrid bolus and continuous infusion interleukin-2 regimen</title></json:item><json:item><author><json:item><name>SD Fossa</name></json:item><json:item><name>ST De Garis</name></json:item><json:item><name>MS Heier</name></json:item></author><host><volume>57</volume><pages><last>1704</last><first>1700</first></pages><author></author><title>Cancer</title></host><title>Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma</title></json:item><json:item><author><json:item><name>AC Buzaid</name></json:item><json:item><name>A Robertone</name></json:item><json:item><name>C Kisala</name></json:item><json:item><name>SE Salmon</name></json:item></author><host><volume>5</volume><pages><last>1089</last><first>1083</first></pages><author></author><title>J Clin Oncol</title></host><title>Phase II study of interferon alfa-2a recombinant (Roferon-A) in metastatic renal cell carcinoma</title></json:item><json:item><author><json:item><name>RA Figlin</name></json:item><json:item><name>JB deKernion</name></json:item><json:item><name>E Mukamel</name></json:item></author><host><volume>6</volume><pages><last>1610</last><first>1604</first></pages><author></author><title>J Clin Oncol</title></host><title>Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation</title></json:item><json:item><author><json:item><name>JP Bergerat</name></json:item><json:item><name>R Herbrecht</name></json:item><json:item><name>P Dufour</name></json:item></author><host><volume>62</volume><pages><last>2324</last><first>2320</first></pages><author></author><title>Cancer</title></host><title>Combination of recombinant interferon alpha2a and vinblastine in advanced renal cell cancer</title></json:item><json:item><author><json:item><name>SA Rosenberg</name></json:item><json:item><name>MT Lotze</name></json:item><json:item><name>JC Yang</name></json:item></author><host><volume>7</volume><pages><last>1874</last><first>1863</first></pages><author></author><title>J Clin Oncol</title></host><title>Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer</title></json:item><json:item><author><json:item><name>J Atzpodien</name></json:item><json:item><name>A Korfer</name></json:item><json:item><name>CR Franks</name></json:item><json:item><name>H Poliwoda</name></json:item><json:item><name>H Kirchner</name></json:item></author><host><volume>335</volume><pages><last>1512</last><first>1509</first></pages><author></author><title>Lancet</title></host><title>Home therapy with recombinant IL2 and recombinant interferon alpha2b in advanced human malignancies</title></json:item><json:item><author><json:item><name>MB Garnick</name></json:item><json:item><name>SD Reich</name></json:item><json:item><name>B Maxwell</name></json:item><json:item><name>S Coval-Goldsmith</name></json:item><json:item><name>JP Richie</name></json:item></author><host><volume>139</volume><pages><last>255</last><first>251</first></pages><author></author><title>J Urol</title></host><title>Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma</title></json:item><json:item><author><json:item><name>W Aulitzky</name></json:item><json:item><name>G Gastl</name></json:item><json:item><name>WE Aulitzky</name></json:item></author><host><volume>7</volume><pages><last>1884</last><first>1875</first></pages><author></author><title>J Clin Oncol</title></host><title>Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma</title></json:item><json:item><author><json:item><name>SM Dubinett</name></json:item><json:item><name>JT Kurnick</name></json:item><json:item><name>RL Kradin</name></json:item></author><host><volume>1</volume><pages><last>369</last><first>361</first></pages><author></author><title>Am J Resp Cell Mol Biol</title></host><title>Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon gamma</title></json:item><json:item><author><json:item><name>B Escudier</name></json:item><json:item><name>F Farace</name></json:item><json:item><name>JP Droz</name></json:item></author><host><author></author><title>Proc Am Soc Clin Oncol</title></host><serie><author></author><title>Proc Am Soc Clin Oncol</title></serie><title>Lymphokine activated natural killer cells may induce shift from partial into complete response in metastatic renal cell carcinoma: an hypothesis</title></json:item><json:item><author><json:item><name>T Hercend</name></json:item><json:item><name>F Farace</name></json:item><json:item><name>D Baume</name></json:item></author><host><volume>9</volume><pages><last>555</last><first>546</first></pages><author></author><title>J Biol Res Mod</title></host><title>Immunotherapy with lymphokine activated natural killer (LANAK) cells and rIL-2: a feasibility trial in metastatic renal cell carcinoma</title></json:item><json:item><author><json:item><name>HF Pross</name></json:item><json:item><name>MG Baines</name></json:item><json:item><name>P Rubin</name></json:item></author><host><volume>1</volume><pages><last>63</last><first>51</first></pages><author></author><title>J Clin Immunol</title></host><title>Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantification of natural killer cell activity</title></json:item><json:item><author><json:item><name>SN Bock</name></json:item><json:item><name>RE Lee</name></json:item><json:item><name>B Fisher</name></json:item></author><host><volume>8</volume><pages><last>169</last><first>161</first></pages><author></author><title>J Clin Oncol</title></host><title>A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy</title></json:item><json:item><author><json:item><name>M Iigo</name></json:item><json:item><name>S Masanori</name></json:item><json:item><name>T Tomohide</name></json:item><json:item><name>S Nagahiro</name></json:item><json:item><name>A Hoshi</name></json:item></author><host><volume>48</volume><pages><last>264</last><first>260</first></pages><author></author><title>Cancer Res</title></host><title>In vivo antitumour activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various synergic murine tumors</title></json:item><json:item><author><json:item><name>JJ Rinehart</name></json:item><json:item><name>D Young</name></json:item><json:item><name>J Laforge</name></json:item><json:item><name>D Colburn</name></json:item><json:item><name>J Neidhart</name></json:item></author><host><volume>6</volume><pages><last>312</last><first>302</first></pages><author></author><title>J Biol Response Mod</title></host><title>Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects</title></json:item><json:item><author><json:item><name>JR Quesada</name></json:item><json:item><name>R Kurzrock</name></json:item><json:item><name>SA Sherwin</name></json:item><json:item><name>JU Gutterman</name></json:item></author><host><volume>6</volume><pages><last>27</last><first>20</first></pages><author></author><title>J Biol Response Mod</title></host><title>Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma</title></json:item><json:item><author><json:item><name>JP Droz</name></json:item><json:item><name>C Theodore</name></json:item><json:item><name>M Ghosn</name></json:item></author><host><volume>4</volume><pages><last>99</last><first>97</first></pages><author></author><title>Semin Surg Oncol</title></host><title>Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave Roussy</title></json:item><json:item><author><json:item><name>F Farace</name></json:item><json:item><name>C Mathiot</name></json:item><json:item><name>M Brandely</name></json:item></author><host><volume>82</volume><pages><last>199</last><first>194</first></pages><author></author><title>Clin Exp Immunol</title></host><title>Phase I trial of recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma</title></json:item><json:item><author><json:item><name>JY Blay</name></json:item><json:item><name>MC Favrot</name></json:item><json:item><name>S Negrier</name></json:item></author><host><volume>50</volume><pages><last>2374</last><first>2371</first></pages><author></author><title>Cancer Res</title></host><title>Correlation between clinical response to IL2 therapy sustaine production of TNF</title></json:item><json:item><author><json:item><name>KA Margolin</name></json:item><json:item><name>AA Rayner</name></json:item><json:item><name>MJ Hawkins</name></json:item></author><host><volume>7</volume><pages><last>498</last><first>486</first></pages><author></author><title>J Clin Oncol</title></host><title>Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors; analysis of toxicity and management guidelines</title></json:item><json:item><author><json:item><name>JC Guillaume</name></json:item><json:item><name>B Escudier</name></json:item><json:item><name>E Espagne</name></json:item></author><host><volume>117</volume><pages><last>902</last><first>899</first></pages><author></author><title>Ann Dermatol Venereol</title></host><title>Dermatose bulleuse avec dépôts linéaires d'IgA le long de la membrane basale au cours d'un traitement par l'association interféron gamma-interleukine 2</title></json:item><json:item><author><json:item><name>BH Ault</name></json:item><json:item><name>FB Stapleton</name></json:item><json:item><name>L Gaber</name></json:item></author><host><volume>319</volume><pages><last>1400</last><first>1397</first></pages><author></author><title>N Eng J Med</title></host><title>Acute renal failure during therapy with recombinant human gamma interferon</title></json:item><json:item><author><json:item><name>WL Ramseur</name></json:item><json:item><name>F Richards, II</name></json:item><json:item><name>DB Buggan</name></json:item></author><host><volume>63</volume><pages><last>2007</last><first>2005</first></pages><author></author><title>Cancer</title></host><title>A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy</title></json:item></refBibs><genre><json:string>research-article</json:string></genre><serie><pages><first>A527</first></pages><language><json:string>unknown</json:string></language><title>Proc Am Soc Clin Oncol</title></serie><host><volume>29</volume><pii><json:string>S0959-8049(05)X8338-1</json:string></pii><pages><last>728</last><first>724</first></pages><issn><json:string>0959-8049</json:string></issn><issue>5</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><title>European Journal of Cancer</title><publicationDate>1993</publicationDate></host><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1016/S0959-8049(05)80354-5</json:string></doi><id>4202F1CA50D86135E197329521FF9741A217E049</id><score>0.14414507</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/4202F1CA50D86135E197329521FF9741A217E049/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/4202F1CA50D86135E197329521FF9741A217E049/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4202F1CA50D86135E197329521FF9741A217E049/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©1993 Pergamon Press Ltd</p></availability><date>1993</date></publicationStmt><notesStmt><note type="content">Section title: Paper</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title><author xml:id="author-1"><persName><forename type="first">B.</forename><surname>Escudier</surname></persName><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><affiliation>Correspondence to B. Escudier.</affiliation></author><author xml:id="author-2"><persName><forename type="first">S.</forename><surname>Antoun</surname></persName><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">B.</forename><surname>Leclercq</surname></persName><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">G.</forename><surname>Nitenberg</surname></persName><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">F.</forename><surname>Farace</surname></persName><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">E.</forename><surname>Angevin</surname></persName><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-7"><persName><forename type="first">F.</forename><surname>Triebel</surname></persName><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-8"><persName><forename type="first">T.</forename><surname>Hercend</surname></persName><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-9"><persName><forename type="first">A.</forename><surname>Aboudaram</surname></persName><affiliation>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation></author><author xml:id="author-10"><persName><forename type="first">M.</forename><surname>Brandely</surname></persName><affiliation>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</affiliation></author></analytic><monogr><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="pISSN">0959-8049</idno><idno type="PII">S0959-8049(05)X8338-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1993"></date><biblScope unit="volume">29</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="724">724</biblScope><biblScope unit="page" to="728">728</biblScope></imprint></monogr><idno type="istex">4202F1CA50D86135E197329521FF9741A217E049</idno><idno type="DOI">10.1016/S0959-8049(05)80354-5</idno><idno type="PII">S0959-8049(05)80354-5</idno><idno type="ArticleID">05803545</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 106 U/m2 for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 106 U/m2 on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.</p></abstract></profileDesc><revisionDesc><change when="1992-08-04">Modified</change><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/4202F1CA50D86135E197329521FF9741A217E049/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><article version="5.0" xml:lang="en" docsubtype="fla"><item-info><jid>EJC</jid><aid>05803545</aid><ce:pii>S0959-8049(05)80354-5</ce:pii><ce:doi>10.1016/S0959-8049(05)80354-5</ce:doi><ce:copyright type="unknown" year="1993">Pergamon Press Ltd</ce:copyright></item-info><head><ce:dochead><ce:textfn>Paper</ce:textfn></ce:dochead><ce:title>Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</ce:title><ce:author-group><ce:author><ce:given-name>B.</ce:given-name><ce:surname>Escudier</ce:surname><ce:cross-ref refid="aff1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>S.</ce:given-name><ce:surname>Antoun</ce:surname><ce:cross-ref refid="aff1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>B.</ce:given-name><ce:surname>Leclercq</ce:surname><ce:cross-ref refid="aff1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>G.</ce:given-name><ce:surname>Nitenberg</ce:surname><ce:cross-ref refid="aff1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>F.</ce:given-name><ce:surname>Farace</ce:surname><ce:cross-ref refid="aff2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>E.</ce:given-name><ce:surname>Angevin</ce:surname><ce:cross-ref refid="aff2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>F.</ce:given-name><ce:surname>Triebel</ce:surname><ce:cross-ref refid="aff2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>T.</ce:given-name><ce:surname>Hercend</ce:surname><ce:cross-ref refid="aff2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>A.</ce:given-name><ce:surname>Aboudaram</ce:surname><ce:cross-ref refid="aff3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M.</ce:given-name><ce:surname>Brandely</ce:surname><ce:cross-ref refid="aff4"><ce:sup>4</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>1</ce:label><ce:textfn>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>2</ce:label><ce:textfn>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>3</ce:label><ce:textfn>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>4</ce:label><ce:textfn>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>1</ce:label><ce:text>Correspondence to B. Escudier.</ce:text></ce:correspondence></ce:author-group><ce:date-revised day="4" month="8" year="1992"></ce:date-revised><ce:date-accepted day="15" month="9" year="1992"></ce:date-accepted><ce:abstract id="ab1" class="author" xml:lang="en"><ce:abstract-sec><ce:simple-para>The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 10<ce:sup loc="post">6</ce:sup> U/m<ce:sup loc="post">2</ce:sup> for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 10<ce:sup loc="post">6</ce:sup> U/m<ce:sup loc="post">2</ce:sup> on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.</ce:simple-para></ce:abstract-sec></ce:abstract></head><tail><ce:bibliography><ce:section-title>References</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>1.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rosenberg</ce:surname><ce:given-name>SA</ce:given-name></sb:author><sb:author><ce:surname>Lotze</ce:surname><ce:given-name>MT</ce:given-name></sb:author><sb:author><ce:surname>Muul</ce:surname><ce:given-name>LM</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>889</sb:first-page><sb:last-page>897</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fisher</ce:surname><ce:given-name>RI</ce:given-name></sb:author><sb:author><ce:surname>Coltman</ce:surname><ce:given-name>CA</ce:given-name></sb:author><sb:author><ce:surname>Doroshow</ce:surname><ce:given-name>JH</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. A phase II clinical trial</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Intern Med</sb:maintitle></sb:title><sb:volume-nr>108</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>518</sb:first-page><sb:last-page>523</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Negrier</ce:surname><ce:given-name>S</ce:given-name></sb:author><sb:author><ce:surname>Philip</ce:surname><ce:given-name>T</ce:given-name></sb:author><sb:author><ce:surname>Stoter</ce:surname><ce:given-name>G</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicenter study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur J Cancer Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>S21</sb:first-page><sb:last-page>S28</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rosenberg</ce:surname><ce:given-name>SA</ce:given-name></sb:author><sb:author><ce:surname>Lotze</ce:surname><ce:given-name>MT</ce:given-name></sb:author><sb:author><ce:surname>Muul</ce:surname><ce:given-name>LM</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>313</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>1485</sb:first-page><sb:last-page>1492</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>West</ce:surname><ce:given-name>WH</ce:given-name></sb:author><sb:author><ce:surname>Tauer</ce:surname><ce:given-name>KW</ce:given-name></sb:author><sb:author><ce:surname>Yanelli</ce:surname><ce:given-name>JR</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Engl J Med</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>898</sb:first-page><sb:last-page>905</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Parkinson</ce:surname><ce:given-name>DR</ce:given-name></sb:author><sb:author><ce:surname>Fisher</ce:surname><ce:given-name>RI</ce:given-name></sb:author><sb:author><ce:surname>Rayner</ce:surname><ce:given-name>AA</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Therapy of renal cell cancer carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hydrid bolus and continuous infusion interleukin-2 regimen</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>1630</sb:first-page><sb:last-page>1636</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fossa</ce:surname><ce:given-name>SD</ce:given-name></sb:author><sb:author><ce:surname>De Garis</ce:surname><ce:given-name>ST</ce:given-name></sb:author><sb:author><ce:surname>Heier</ce:surname><ce:given-name>MS</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>1700</sb:first-page><sb:last-page>1704</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Buzaid</ce:surname><ce:given-name>AC</ce:given-name></sb:author><sb:author><ce:surname>Robertone</ce:surname><ce:given-name>A</ce:given-name></sb:author><sb:author><ce:surname>Kisala</ce:surname><ce:given-name>C</ce:given-name></sb:author><sb:author><ce:surname>Salmon</ce:surname><ce:given-name>SE</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Phase II study of interferon alfa-2a recombinant (Roferon-A) in metastatic renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>1083</sb:first-page><sb:last-page>1089</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Figlin</ce:surname><ce:given-name>RA</ce:given-name></sb:author><sb:author><ce:surname>deKernion</ce:surname><ce:given-name>JB</ce:given-name></sb:author><sb:author><ce:surname>Mukamel</ce:surname><ce:given-name>E</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>1604</sb:first-page><sb:last-page>1610</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bergerat</ce:surname><ce:given-name>JP</ce:given-name></sb:author><sb:author><ce:surname>Herbrecht</ce:surname><ce:given-name>R</ce:given-name></sb:author><sb:author><ce:surname>Dufour</ce:surname><ce:given-name>P</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Combination of recombinant interferon alpha2a and vinblastine in advanced renal cell cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer</sb:maintitle></sb:title><sb:volume-nr>62</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>2320</sb:first-page><sb:last-page>2324</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rosenberg</ce:surname><ce:given-name>SA</ce:given-name></sb:author><sb:author><ce:surname>Lotze</ce:surname><ce:given-name>MT</ce:given-name></sb:author><sb:author><ce:surname>Yang</ce:surname><ce:given-name>JC</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>1863</sb:first-page><sb:last-page>1874</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Atzpodien</ce:surname><ce:given-name>J</ce:given-name></sb:author><sb:author><ce:surname>Korfer</ce:surname><ce:given-name>A</ce:given-name></sb:author><sb:author><ce:surname>Franks</ce:surname><ce:given-name>CR</ce:given-name></sb:author><sb:author><ce:surname>Poliwoda</ce:surname><ce:given-name>H</ce:given-name></sb:author><sb:author><ce:surname>Kirchner</ce:surname><ce:given-name>H</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Home therapy with recombinant IL2 and recombinant interferon alpha2b in advanced human malignancies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>335</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>1509</sb:first-page><sb:last-page>1512</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Garnick</ce:surname><ce:given-name>MB</ce:given-name></sb:author><sb:author><ce:surname>Reich</ce:surname><ce:given-name>SD</ce:given-name></sb:author><sb:author><ce:surname>Maxwell</ce:surname><ce:given-name>B</ce:given-name></sb:author><sb:author><ce:surname>Coval-Goldsmith</ce:surname><ce:given-name>S</ce:given-name></sb:author><sb:author><ce:surname>Richie</ce:surname><ce:given-name>JP</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Urol</sb:maintitle></sb:title><sb:volume-nr>139</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>251</sb:first-page><sb:last-page>255</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Aulitzky</ce:surname><ce:given-name>W</ce:given-name></sb:author><sb:author><ce:surname>Gastl</ce:surname><ce:given-name>G</ce:given-name></sb:author><sb:author><ce:surname>Aulitzky</ce:surname><ce:given-name>WE</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>1875</sb:first-page><sb:last-page>1884</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Dubinett</ce:surname><ce:given-name>SM</ce:given-name></sb:author><sb:author><ce:surname>Kurnick</ce:surname><ce:given-name>JT</ce:given-name></sb:author><sb:author><ce:surname>Kradin</ce:surname><ce:given-name>RL</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon gamma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am J Resp Cell Mol Biol</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>361</sb:first-page><sb:last-page>369</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Escudier</ce:surname><ce:given-name>B</ce:given-name></sb:author><sb:author><ce:surname>Farace</ce:surname><ce:given-name>F</ce:given-name></sb:author><sb:author><ce:surname>Droz</ce:surname><ce:given-name>JP</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Lymphokine activated natural killer cells may induce shift from partial into complete response in metastatic renal cell carcinoma: an hypothesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc Am Soc Clin Oncol</sb:maintitle></sb:title></sb:series></sb:book-series><sb:date>1991</sb:date></sb:edited-book><sb:pages><sb:first-page>A527</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hercend</ce:surname><ce:given-name>T</ce:given-name></sb:author><sb:author><ce:surname>Farace</ce:surname><ce:given-name>F</ce:given-name></sb:author><sb:author><ce:surname>Baume</ce:surname><ce:given-name>D</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Immunotherapy with lymphokine activated natural killer (LANAK) cells and rIL-2: a feasibility trial in metastatic renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Biol Res Mod</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>546</sb:first-page><sb:last-page>555</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>18.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Pross</ce:surname><ce:given-name>HF</ce:given-name></sb:author><sb:author><ce:surname>Baines</ce:surname><ce:given-name>MG</ce:given-name></sb:author><sb:author><ce:surname>Rubin</ce:surname><ce:given-name>P</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantification of natural killer cell activity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Immunol</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>1981</sb:date></sb:issue><sb:pages><sb:first-page>51</sb:first-page><sb:last-page>63</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>19.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bock</ce:surname><ce:given-name>SN</ce:given-name></sb:author><sb:author><ce:surname>Lee</ce:surname><ce:given-name>RE</ce:given-name></sb:author><sb:author><ce:surname>Fisher</ce:surname><ce:given-name>B</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>161</sb:first-page><sb:last-page>169</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>20.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Iigo</ce:surname><ce:given-name>M</ce:given-name></sb:author><sb:author><ce:surname>Masanori</ce:surname><ce:given-name>S</ce:given-name></sb:author><sb:author><ce:surname>Tomohide</ce:surname><ce:given-name>T</ce:given-name></sb:author><sb:author><ce:surname>Nagahiro</ce:surname><ce:given-name>S</ce:given-name></sb:author><sb:author><ce:surname>Hoshi</ce:surname><ce:given-name>A</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle><ce:italic>In vivo</ce:italic> antitumour activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various synergic murine tumors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res</sb:maintitle></sb:title><sb:volume-nr>48</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>260</sb:first-page><sb:last-page>264</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>21.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rinehart</ce:surname><ce:given-name>JJ</ce:given-name></sb:author><sb:author><ce:surname>Young</ce:surname><ce:given-name>D</ce:given-name></sb:author><sb:author><ce:surname>Laforge</ce:surname><ce:given-name>J</ce:given-name></sb:author><sb:author><ce:surname>Colburn</ce:surname><ce:given-name>D</ce:given-name></sb:author><sb:author><ce:surname>Neidhart</ce:surname><ce:given-name>J</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Biol Response Mod</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>302</sb:first-page><sb:last-page>312</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>22.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Quesada</ce:surname><ce:given-name>JR</ce:given-name></sb:author><sb:author><ce:surname>Kurzrock</ce:surname><ce:given-name>R</ce:given-name></sb:author><sb:author><ce:surname>Sherwin</ce:surname><ce:given-name>SA</ce:given-name></sb:author><sb:author><ce:surname>Gutterman</ce:surname><ce:given-name>JU</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Biol Response Mod</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>20</sb:first-page><sb:last-page>27</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>23.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Droz</ce:surname><ce:given-name>JP</ce:given-name></sb:author><sb:author><ce:surname>Theodore</ce:surname><ce:given-name>C</ce:given-name></sb:author><sb:author><ce:surname>Ghosn</ce:surname><ce:given-name>M</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave Roussy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Semin Surg Oncol</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>97</sb:first-page><sb:last-page>99</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>24.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Farace</ce:surname><ce:given-name>F</ce:given-name></sb:author><sb:author><ce:surname>Mathiot</ce:surname><ce:given-name>C</ce:given-name></sb:author><sb:author><ce:surname>Brandely</ce:surname><ce:given-name>M</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Phase I trial of recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Exp Immunol</sb:maintitle></sb:title><sb:volume-nr>82</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>194</sb:first-page><sb:last-page>199</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>25.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blay</ce:surname><ce:given-name>JY</ce:given-name></sb:author><sb:author><ce:surname>Favrot</ce:surname><ce:given-name>MC</ce:given-name></sb:author><sb:author><ce:surname>Negrier</ce:surname><ce:given-name>S</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Correlation between clinical response to IL2 therapy sustaine production of TNF</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>2371</sb:first-page><sb:last-page>2374</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>26.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Margolin</ce:surname><ce:given-name>KA</ce:given-name></sb:author><sb:author><ce:surname>Rayner</ce:surname><ce:given-name>AA</ce:given-name></sb:author><sb:author><ce:surname>Hawkins</ce:surname><ce:given-name>MJ</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors; analysis of toxicity and management guidelines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Clin Oncol</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>486</sb:first-page><sb:last-page>498</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>27.</ce:label><sb:reference><sb:contribution langtype="iso" xml:lang="fr"><sb:authors><sb:author><ce:surname>Guillaume</ce:surname><ce:given-name>JC</ce:given-name></sb:author><sb:author><ce:surname>Escudier</ce:surname><ce:given-name>B</ce:given-name></sb:author><sb:author><ce:surname>Espagne</ce:surname><ce:given-name>E</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dermatose bulleuse avec dépôts linéaires d'IgA le long de la membrane basale au cours d'un traitement par l'association interféron gamma-interleukine 2</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann Dermatol Venereol</sb:maintitle></sb:title><sb:volume-nr>117</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>899</sb:first-page><sb:last-page>902</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>28.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ault</ce:surname><ce:given-name>BH</ce:given-name></sb:author><sb:author><ce:surname>Stapleton</ce:surname><ce:given-name>FB</ce:given-name></sb:author><sb:author><ce:surname>Gaber</ce:surname><ce:given-name>L</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Acute renal failure during therapy with recombinant human gamma interferon</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N Eng J Med</sb:maintitle></sb:title><sb:volume-nr>319</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>1397</sb:first-page><sb:last-page>1400</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>29.</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Ramseur</ce:surname><ce:given-name>WL</ce:given-name></sb:author><sb:author><ce:surname>Richards</ce:surname><ce:given-name>F</ce:given-name><ce:suffix>II</ce:suffix></sb:author><sb:author><ce:surname>Buggan</ce:surname><ce:given-name>DB</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer</sb:maintitle></sb:title><sb:volume-nr>63</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>2005</sb:first-page><sb:last-page>2007</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma</title></titleInfo><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Escudier</namePart><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><affiliation>Correspondence to B. Escudier.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Antoun</namePart><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Leclercq</namePart><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Nitenberg</namePart><affiliation>the Service de Réanimation, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Farace</namePart><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Angevin</namePart><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Triebel</namePart><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Hercend</namePart><affiliation>the Laboratoire d'Hémato-Immunologie, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Aboudaram</namePart><affiliation>the Service de Radiodiagnostic, Institut Gustave Roussy, 35 rue Camille Desmoulins, 94805 Villejuif, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Brandely</namePart><affiliation>the Roussel UCLAF, 102 route de Noisy, 93230 Romainville, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1993</dateIssued><dateModified encoding="w3cdtf">1992-08-04</dateModified><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The use of high-dose interleukin-2 (IL2), alone or in association with lymphokine activated killer cells in patients with metastatic renal cell carcinoma (MRCC) results in a 20–25% response rate. However, the toxicity of IL2 is substantial and despite many clinical trials, response rates initially reported have not been improved. The aim of this study was to evaluate a combination of IL2 and gamma interferon (IFN) in MRCC with respect to both efficacy and tolerance. IL2 was given by continuous intravenous infusion at a daily dose of 24 × 106 U/m2 for 2 consecutive days during 5 consecutive weeks. Gamma IFN was given subcutaneously at a daily dose of 5 × 106 U/m2 on the same days as IL2. 33 patients with MRCC entered the study. Clinical responses were comparable with other published series: 7 patients (21%) achieved partial response, 13 (39%) were stable and 13 had progression, despite therapy. Immunological profile observed with this regimen showed a major increase in natural killer cells which became the predominant lymphocyte population at the end of the therapy. Tolerance was good with 92.5% of the planned doses actually received by the patients. This was reflected by an early discharge from the hospital in 95% of the cycles, increasing acceptability of the regimen by the patients.</abstract><note type="content">Section title: Paper</note><relatedItem type="host"><titleInfo><title>European Journal of Cancer</title></titleInfo><titleInfo type="abbreviated"><title>EJC</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">1993</dateIssued></originInfo><identifier type="ISSN">0959-8049</identifier><identifier type="PII">S0959-8049(05)X8338-1</identifier><part><date>1993</date><detail type="volume"><number>29</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue pages"><start>655</start><end>789</end></extent><extent unit="pages"><start>724</start><end>728</end></extent></part></relatedItem><identifier type="istex">4202F1CA50D86135E197329521FF9741A217E049</identifier><identifier type="DOI">10.1016/S0959-8049(05)80354-5</identifier><identifier type="PII">S0959-8049(05)80354-5</identifier><identifier type="ArticleID">05803545</identifier><accessCondition type="use and reproduction" contentType="copyright">©1993 Pergamon Press Ltd</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Pergamon Press Ltd, ©1993</recordOrigin></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4202F1CA50D86135E197329521FF9741A217E049
|texte= Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma
}}
| This area was generated with Dilib version V0.6.29. |  |